Welcome to our dedicated page for GLOBUS MEDICAL SEC filings (Ticker: GMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GLOBUS MEDICAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GLOBUS MEDICAL's regulatory disclosures and financial reporting.
Globus Medical Inc. director David D. Davidar reported a bona fide gift of 2,500 shares of Class A Common Stock on July 27, 2026, at $0.00 per share. After the gift, he directly holds 507,675 shares and has indirect ownership of 165,967 shares held in the Davidar Family Irrevocable Trust U/A 8/6/09 for the benefit of his spouse and children, with his spouse serving as trustee. The filing indicates this transaction was not made under a Rule 10b5-1 trading plan.
Globus Medical director David D. Davidar reported an exercise-and-sell transaction in Class A common stock. He exercised stock options for 25,000 shares at $26.27 per share and sold 25,000 shares in an open-market transaction at a weighted average price of $80.7629 per share.
Following these moves, Davidar directly holds 510,175 shares of Class A common stock. In addition, a family irrevocable trust established on August 6, 2009 holds 165,967 shares for the benefit of his spouse and children, with his spouse serving as trustee.
Globus Medical director Ann D. Rhoads exercised stock options to acquire 25,000 shares of Class A Common Stock at $26.27 per share. These options were granted on January 30, 2017 and were fully vested at exercise. Following the transaction, she directly owns 40,384 shares, and this filing shows no related share sales.
Globus Medical, Inc. held its 2026 Annual Meeting of Stockholders, where stockholders approved an amendment to the 2021 Equity Incentive Plan to add 1,000,000 additional shares, bringing the total shares authorized for issuance under the plan to 12,000,000 Class A common shares.
The amendment also raised the limit on shares that may be issued as incentive stock options to 12,000,000. Stockholders elected two Class II directors to serve until the 2029 annual meeting, ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, and approved 2025 executive compensation on an advisory basis.
Globus Medical, Inc. reported sharply higher quarterly results for the three months ended March 31, 2026. Net sales rose to $759.9 million from $598.1 million a year earlier, while net income increased to $124.3 million from $75.5 million. Diluted earnings per share improved to $0.90 from $0.54.
Growth came from both U.S. and international markets and reflects the integration of the 2025 Nevro acquisition, which contributed $82.7 million in revenue. The company generated $202.4 million in cash from operating activities, maintained a strong cash and investments position, and recorded ongoing restructuring and acquisition-related costs while continuing to invest in R&D and enabling technologies.
Globus Medical delivered a strong start to 2026, with first quarter worldwide net sales of $759.9 million, up 27.0% year over year, or 25.5% on a constant currency basis. Base business net sales excluding Nevro were $677.2 million, up 13.2%.
GAAP net income rose to $124.3 million, an increase of 64.7%, while GAAP diluted EPS climbed to $0.90. Non-GAAP diluted EPS was $1.12, up 64.7%. Net sales from the Nevro acquisition contributed $82.7 million in the quarter.
The company reaffirmed its 2026 revenue outlook of $3.18 billion to $3.22 billion and raised its full-year non-GAAP diluted EPS guidance to $4.70–$4.80 from $4.40–$4.50, reflecting margin expansion and expected benefits from operating leverage and acquisition synergies.
Vanguard Capital Management reports beneficial ownership of 5,885,560 shares of Globus Medical Inc. common stock, representing 5.22% of the class. The filing shows sole voting power for 852,828 shares and sole dispositive power for 5,885,560 shares.
Globus Medical, Inc. will hold its 2026 annual stockholder meeting on June 3, 2026 at its Pennsylvania headquarters. Stockholders will vote to elect two Class II directors, amend the 2021 Equity Incentive Plan to add 1,000,000 Class A shares, ratify Deloitte & Touche LLP as auditor, and approve executive pay on an advisory basis.
Holders of Class A and Class B common stock as of April 13, 2026 may vote in person or by Internet, phone, or mail. The company describes how broker non-votes, abstentions, and its NYSE "controlled company" status affect governance and voting outcomes.